专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO1995022329A1 AGENT FOR PROPHYLAXIS AND TREATMENT OF THROMBOXANE A2-MEDIATED DISEASES 审中-公开
标题翻译：丙型肝炎治疗和治疗甲硫氨酸A2介导性疾病
公开(公告)号：WO1995022329A1
公开(公告)日：1995-08-24
申请号：PCT/JP1995000244
申请日：1995-02-20
申请人： THE GREEN CROSS CORPORATION , NISSAN CHEMICAL INDUSTRIES, LTD. , IKEGAWA, Ruriko , IMADA, Teruaki , NAKAMURA, Norifumi , TANIKAWA, Keizo , TSURUZOE, Nobutomo
发明人： THE GREEN CROSS CORPORATION , NISSAN CHEMICAL INDUSTRIES, LTD.
IPC分类号： A61K31/50
CPC分类号： A61K31/501 , A61K31/50
摘要： An agent for the prophylaxis or treatment of TXA2-mediated diseases, particularly, a TXA2 synthetase inhibitor, which comprises a pyridazinone compound of formula (I), wherein each symbol is as defined in the specification, or a pharmacologically acceptable salt thereof as an active ingredient. The pyridazinone compound (I) and pharmacologically acceptable salts thereof used in the present invention have prophylactic and therapeutic activities against TXA2-mediated diseases, particularly a TXA2 synthetase inhibitory action and are useful as an agent for the prophylaxis or treatment of TXA2-mediated diseases, particularly as TXA2 synthetase inhibitors.
摘要翻译：用于预防或治疗TXA2介导的疾病的药剂，特别是TXA2合成酶抑制剂，其包含式（I）的哒嗪酮化合物，其中每个符号如说明书中所定义，或其药理学上可接受的盐作为活性物质成分。用于本发明的哒嗪酮化合物（I）及其药理学上可接受的盐具有抗TXA2介导的疾病，特别是TXA2合成酶抑制作用的预防和治疗活性，可用作预防或治疗TXA2介导的疾病，特别是作为TXA2合成酶抑制剂。

2. 发明申请

WO1995019969A1 PYRIDAZINONE DERIVATIVE 审中-公开
标题翻译：吡咯烷酮衍生物
公开(公告)号：WO1995019969A1
公开(公告)日：1995-07-27
申请号：PCT/JP1995000069
申请日：1995-01-24
申请人： NISSAN CHEMICAL INDUSTRIES, LTD. , TANIKAWA, Keizo , MATSUMOTO, Takashi , MATSUMOTO, Hiroo , TSURUZOE, Nobutomo , NAKABEPPU, Hitoshi
发明人： NISSAN CHEMICAL INDUSTRIES, LTD.
IPC分类号： C07D237/22
CPC分类号： C07D401/12 , C07D237/22
摘要： A pyridazinone derivative represented by general formula (I) and an antithrombocytic agent containing the same, wherein R represents hydrogen or C1-C4 alkyl; X represents hydrogen, chlorine or bromine; An represents pyridyl or phenyl substituted by OR (R representing hydrogen or C1-C4 alkyl) and A (representing hydrogen, halogen, C1-C4 alkyl or OR (R representing hydrogen or C1-C4 alkyl)); Y represents C1-C8 alkylene wherein one carbon atom on the straight chain is substituted by one OR group (R being as defined as above); and Z and Z represent each independently hydrogen, halogen, C1-C4 alkyl or OR (R being as defined above). This compound has a potent antithrombocytic activity and an excellent safety and is used as the active ingredient of a preventive or remedy for various thrombotic diseases.
摘要翻译：由通式（I）表示的哒嗪酮衍生物和含有它的抗血栓形成剂，其中R表示氢或C1-C4烷基; X表示氢，氯或溴; A代表由OR 1取代的吡啶基或苯基（R 1代表氢或C 1 -C 4烷基）和A（代表氢，卤素，C 1 -C 4烷基或OR 2（R 2代表氢或C 1 -C4烷基））; Y表示直链上的一个碳原子被一个OR 1基团取代的C1-C8亚烷基（R 1如上所定义）; Z 1和Z 2各自独立地表示氢，卤素，C 1 -C 4烷基或OR 1（R 1如上所定义）。该化合物具有有效的抗血栓形成细胞活性和优异的安全性，并被用作各种血栓性疾病的预防或治疗的活性成分。

3. 发明申请

WO1998004542A1 CHROMAN DERIVATIVES 审中-公开
公开(公告)号：WO1998004542A1
公开(公告)日：1998-02-05
申请号：PCT/JP1997002583
申请日：1997-07-25
申请人： NISSAN CHEMICAL INDUSTRIES, LTD. , TANIKAWA, Keizo , OHRAI, Kazuhiko , SATO, Masayuki , YAMASHITA, Toru , YANAGIHARA, Kazufumi
发明人： NISSAN CHEMICAL INDUSTRIES, LTD.
IPC分类号： C07D311/70
CPC分类号： C07D405/04 , C07D311/70 , C07D405/12 , C07D407/12 , C07D409/12 , C07F7/1804
摘要： The present invention relates to chroman derivatives of formula (I): wherein R represents a hydrogen atom, a halogen atom, a C1-6 alkyl group, a C1-6 alkoxy group, a C3-6 alkoxymethyl group, etc.; R and R each independently represent a hydrogen atom, a C1-6 alkyl group, etc.; R represents a hydroxyl group or a C1-6 alkylcarbonyloxyl group or forms a bond together with R ; R represents a hydrogen atom or forms a bond together with R ; R and R each independently represent a hydrogen atom, a C1-6 alkyl group, a C3-6 cycloalkyl group, a phenyl group, etc.; n is 0 or an integer of 1, 2, 3, or 4; W represents a phenyl group, etc.; X represents C=O, CH2, SO2, etc.; Y represents NR (in which R represents a hydrogen atom, a C1-4 alkyl group, a phenyl group, etc.), etc.; Z does not exist or represents CH2 or NR (R represents a hydrogen atom, a C1-4 alkyl group, or a phenyl group, etc.) or their salts.
摘要翻译：本发明涉及式（I）的苯并二氢吡喃衍生物：其中R 1表示氢原子，卤素原子，C 1-6烷基，C 1-6烷氧基，C 3-6烷氧基甲基等。 ; R 3和R 4各自独立地表示氢原子，C 1-6烷基等; R 5代表羟基或C 1-6烷基羰基氧基或与R 5一起形成键; R 6表示氢原子或与R 5一起形成键; R 7和R 8各自独立地表示氢原子，C 1-6烷基，C 3-6环烷基，苯基等; n为0或1，2，3或4的整数; W表示苯基等; X表示C = O，CH 2，SO 2等; Y表示NR 17（其中R 17表示氢原子，C 1-4烷基，苯基等）等; Z不存在或表示CH 2或NR 18（R 18表示氢原子，C 1-4烷基或苯基等）或其盐。

4. 发明申请

WO1995006053A1 TRIS(SUBSTITUTED PHENYL)BISMUTH DERIVATIVE 审中-公开
标题翻译： TRIS（取代苯乙烯）双酚衍生物
公开(公告)号：WO1995006053A1
公开(公告)日：1995-03-02
申请号：PCT/JP1994001381
申请日：1994-08-22
申请人： NISSAN CHEMICAL INDUSTRIES, LTD. , SUZUKI, Hitomi , MAEDA, Kouichi , TANIKAWA, Keizo , MIYAJI, Katsuaki
发明人： NISSAN CHEMICAL INDUSTRIES, LTD.
IPC分类号： C07F09/94
CPC分类号： A61K49/04 , C07F9/94 , Y10S424/90
摘要： A tris(substituted phenyl)bismuth derivative represented by general formula (I) and, if any, a pharmaceutically acceptable salt thereof, wherein X represents Y -NR R [wherein Y represents -SO2- or -C(=O)-; and R and R represent each independently hydrogen, C1-C4 alkyl or A-Z (wherein A represents alkylene which has 2-6 carbon atoms in total and may have a branch having at least two carbon atoms, and Z represents OR (wherein R represents SiR R R (wherein R , R and R represent each independently C1-C4 alkyl or phenyl), hydrogen or C1-C4 alkyl) or NR R (wherein R and R represent each independently hydrogen or C1-C4 alkyl)), provided the case where R and R are both hydrogen atoms is excepted], -O-CHR -OR (wherein R represents C1-C4 alkyl, and R is as defined above) or Y -A-Z [wherein Y represents O, -S(O)n- (wherein n represents an integer of 0 or 2) or -NR - (wherein R is as defined above), and A and Z are each as defined above]; and X and X represent each independently hydrogen or any substituent defined above with respect to X . This compound has an excellent performance as a radio-logical contrast medium and is useful as an X-ray contrast medium for injecting into a blood vessel, urinary tract, and so forth.
摘要翻译：由通式（I）表示的三（取代的苯基）铋衍生物和（如果有的话）其药学上可接受的盐，其中X 1表示Y 1 -NR 1 R 2 [其中Y 1 >表示-SO 2 - 或-C（= O） - ; 并且R 1和R 2各自独立地表示氢，C 1 -C 4烷基或AZ（其中A表示总共具有2-6个碳原子并且可具有至少两个碳原子的支链的亚烷基，Z表示 OR 3（其中R 3表示SiR 4 R 5 R 6（其中R 4，R 5和R 6各自独立地为C 1 -C 4烷基或苯基），氢或C 1 -C 4烷基）或NR 7 R 8（其中R 7和R 8各自独立地表示氢或C 1 -C 4烷基）），条件是其中R 1和R 2， 2>均为氢原子除外]，-O-CHR 7 -OR 9（其中R 9表示C 1 -C 4烷基，R 7如上定义）或Y 2 - AZ [其中Y 2表示O，-S（O）n - （其中n表示0或2的整数）或-NR 1 - （其中R 1如上所定义），A和 Z各自如上所定义）; X 2和X 3各自独立地表示氢或相对于X 1定义的任何取代基。该化合物作为无线电逻辑造影剂具有优异的性能，并且可用作用于注射到血管，尿道等中的X射线造影剂。

5. 发明申请

WO1997023209A1 THERAPEUTIC AGENT FOR CARDIAC FAILURE 审中-公开
标题翻译：治疗失败的治疗剂
公开(公告)号：WO1997023209A1
公开(公告)日：1997-07-03
申请号：PCT/JP1996003761
申请日：1996-12-24
申请人： NISSAN CHEMICAL INDUSTRIES, LTD. , TANIKAWA, Keizo , OHRAI, Kazuhiko , SATO, Masayuki , YAMASHITA, Toru
发明人： NISSAN CHEMICAL INDUSTRIES, LTD.
IPC分类号： A61K31/35
CPC分类号： C07D311/68 , A61K31/353 , A61K31/397 , A61K31/4025 , A61K31/453 , A61K31/55
摘要： A therapeutic agent for cardiac failure comprising as the active ingredient either a benzopyran derivative represented by general formula (I) or a pharmacologically acceptable salt thereof, wherein R and R each independently represent hydrogen, halogeno, nitro, cyano, amino, C1-6 alkylcarbonylamino, etc.; R and R each independently represents hydrogen, C1-6 alkyl, or phenyl, or R and R are bonded together to form C3-6 cycloalkyl in cooperation with the carbon atom bonded thereto; R represents hydroxy, C1-6 alkoxy, or C1-6 alkylcarbonyloxy, or R is bonded to R to form a bond; R represents hydrogen, or R is bonded to R to form a bond; and R and R each independently represent hydrogen or C1-6 alkyl, or R and R are bonded together to form pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl, etc. in cooperation with the nitrogen atom bonded thereto, or R and R are bonded together to form, in cooperation with the nitrogen atom bonded thereto, pyrrole ring optionally substituted with R (where R has the same meaning as R ).
摘要翻译：一种用于心力衰竭的治疗剂，其包含作为活性成分的通式（I）表示的苯并吡喃衍生物或其药理学上可接受的盐，其中R 1和R 2各自独立地表示氢，卤素，硝基，氰基，氨基，C 1-6烷基羰基氨基等; R 3和R 4各自独立地表示氢，C 1-6烷基或苯基，或者R 3和R 4与键合的碳原子一起形成C 3-6环烷基; R 5表示羟基，C 1-6烷氧基或C 1-6烷基羰基氧基，或R 5与R 6结合形成键; R 6表示氢，或R 6与R 5键合形成键; R 7和R 8各自独立地表示氢或C 1-6烷基，或者R 7和R 8结合在一起形成吡咯烷基，咪唑烷基，吡唑烷基，哌啶基，哌嗪基等，与与其键合的氮原子或R 7和R 8键合在一起，以与其键合的氮原子一起形成任选被R 9取代的吡咯环（其中R 9具有相同的含义作为R 1）。

6. 发明申请

WO1997013757A1 PYRAZOLONE DERIVATIVES 审中-公开
标题翻译：吡唑啉酮衍生物
公开(公告)号：WO1997013757A1
公开(公告)日：1997-04-17
申请号：PCT/JP1996002944
申请日：1996-10-11
申请人： NISSAN CHEMICAL INDUSTRIES, LTD. , TANIKAWA, Keizo , MATSUMOTO, Takashi , NAKAMURA, Masumi , ASADA, Yasunori , SHUDO, Norimasa
发明人： NISSAN CHEMICAL INDUSTRIES, LTD.
IPC分类号： C07D231/22
CPC分类号： C07D231/12 , C07D231/14 , C07D231/20 , C07D231/22 , C07D401/04 , C07D401/06 , C07D401/14 , C07D403/04
摘要： Pyrazolone derivatives represented by general formula (I) or salts thereof which have antiplatelet aggregation effects and thus are useful as a preventive or remedy for various thrombotic diseases. In said formula (I) X and X represents (a), wherein A represents cyano, cyano(C1-4 alkyl), amino, amino-(C1-4 alkyl), amidino, guanidino, etc.; and R and R independently represents each hydrogen, halogeno, C1-6 alkyl, etc.; another of X and X represents C1-6 alkyl, C3-6 alkenyl, aryl(C1-4 alkyl) or aryl; one of Y and Y represents (b), wherein Q represents oxygen or sulfur; Z represents oxygen, -NR - or -CHR -; Z represents cyclic C3-7 alkylene, C1-3 alkylene, -CH2CO-, -CH2CH2CO-, etc.; Z represents oxygen, sulfur, sulfinyl, sulfonyl, etc.; Z represents C1-3 alkylene, etc.; and Z represents carboxyl, etc.; and another of Y and Y represents D-E-, wherein E represents a bond, C1-4 alkylene, phenylene, etc.; and D represents hydrogen, C1-6 alkyl, etc.
摘要翻译：具有抗血小板聚集效应的由通式（I）表示的吡唑啉酮衍生物或其盐，因此可用作各种血栓形成疾病的预防或治疗。在所述式（I）中，X 1和X 2代表（a），其中A表示氰基，氰基（C 1-4烷基），氨基，氨基 - （C 1-4烷基），脒基，胍基等 ; R 1和R 2各自独立地表示氢，卤代C 1-6烷基等; X 1和X 2中的另一个表示C 1-6烷基，C 3-6烯基，芳基（C 1-4烷基）或芳基; Y 1和Y 2中的一个表示（b），其中Q表示氧或硫; Z 1表示氧，-NR 7 - 或-CHR 7 - ; Z 2表示环状C 3-7亚烷基，C 1-3亚烷基，-CH 2 CO-，-CH 2 CH 2 CO-等; Z 3表示氧，硫，亚磺酰基，磺酰基等; Z 4表示C 1-3亚烷基等。 Z 5表示羧基等。 Y 1和Y 2中的另一个表示D-E-，其中E表示键，C 1-4亚烷基，亚苯基等; D表示氢，C 1-6烷基等。

7. 发明申请

WO1996019487A1 ORGANOBISMUTH DERIVATIVES AND PROCESS FOR PRODUCING THE SAME 审中-公开
标题翻译：有机原料衍生物及其生产方法
公开(公告)号：WO1996019487A1
公开(公告)日：1996-06-27
申请号：PCT/JP1995002551
申请日：1995-12-13
申请人： NISSAN CHEMICAL INDUSTRIES, LTD. , SUZUKI, Hitomi , TANIKAWA, Keizo , MIYAJI, Katsuaki , SUZUKI, Nobuhiro
发明人： NISSAN CHEMICAL INDUSTRIES, LTD.
IPC分类号： C07F09/94
CPC分类号： C07F9/94 , A61K49/04 , Y10S424/90
摘要： An organobismuth derivative represented by general formula (I), a salt thereof, and a contrast medium containing the same as the active ingredient: wherein, X represents Y NR R , wherein Y represents -SO2- or -C(O)-, R represents C3-6 alkyl having 2 to 5 hydroxyl groups, R represents hydrogen, C1-6 alkyl optionally having 1 to 5 hydroxyl groups or C1-5 acyl, or R and R together may form C2-6 cycloalkylene optionally having 1 to 4 hydroxyl groups; X and X each independently represent hydrogen, C1-4 alkyl, C1-4 alkoxy, C1-4 alkylsulfonyl, C1-4 alkylcarbonyl, nitro or cyano, or has the same meaning as that of X ; and each of the above hydroxyl groups may be protected.
摘要翻译：一种由通式（I）表示的有机铋衍生物及其盐及含有其的活性成分的造影剂：其中X 1表示Y 1 NR 1 R 2，其中Y < 1表示-SO 2 - 或-C（O） - ，R 1表示具有2至5个羟基的C 3-6烷基，R 2表示氢，任选具有1至5个羟基的C 1-6烷基或C 1 -5酰基或R 1和R 2一起可以形成任选具有1至4个羟基的C 2-6亚环烷基; X 2和X 3各自独立地表示氢，C 1-4烷基，C 1-4烷氧基，C 1-4烷基磺酰基，C 1-4烷基羰基，硝基或氰基，或具有与X 1相同的含义。 ; 并且上述羟基中的每一个可以被保护。

8. 发明申请

WO1994022838A1 PYRAZOLE DERIVATIVE 审中-公开
标题翻译：吡唑衍生物
公开(公告)号：WO1994022838A1
公开(公告)日：1994-10-13
申请号：PCT/JP1994000587
申请日：1994-04-07
申请人： NISSAN CHEMICAL INDUSTRIES, LTD. , TANIKAWA, Keizo , KAMIKAWAJI, Yoshimasa , ODOI, Keisuke , HIGASHIYAMA, Tsutomu , SATO, Masayuki , MASUDA, Yukinori
发明人： NISSAN CHEMICAL INDUSTRIES, LTD.
IPC分类号： C07D231/38
CPC分类号： C07D231/38 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07F9/65583
摘要： A pyrazole compound represented by general formula (1), tautomers thereof, and salts of both; (wherein R represents alkyl, etc.; R represents carboxyl, etc.; R represents halogen, alkyl, phenyl, etc.; R , R and R represent each hydrogen, halogen, etc.; R represents carboxyl, 5-tetrazolyl, etc.; X represents nitrogen, etc.; Y and Z represent each CH, nitrogen, etc.; A and E represent each methylene, etc.; D represents phenyl, etc.; and G represents a covalent bond, etc.), having angiotensin II antagonism and being useful for preventing or treating hypertension, congestive heart failure, chronic renal failure, aldosteronism, increased intraocular pressure, and so forth.
摘要翻译：由通式（1）表示的吡唑化合物，其互变异构体和两者的盐; （其中R 1表示烷基等; R 2表示羧基等; R 3表示卤素，烷基，苯基等; R 4，R 5和R 6，代表每个氢，卤素等; R 7表示羧基，5-四唑基等; X表示氮等; Y和Z表示每个CH，氮等; A和E表示每个亚甲基等，D表示苯基等; G表示共价键等），其具有血管紧张素II拮抗作用，可用于预防或治疗高血压，充血性心力衰竭，慢性肾功能衰竭，醛固酮增多症，眼内压升高等。

9. 发明申请

WO1996034871A1 BENZOPYRAN DERIVATIVES 审中-公开
标题翻译： BENZOPYRAN衍生物
公开(公告)号：WO1996034871A1
公开(公告)日：1996-11-07
申请号：PCT/JP1996001180
申请日：1996-04-30
申请人： NISSAN CHEMICAL INDUSTRIES, LTD. , TANIKAWA, Keizo , OHRAI, Kazuhiko , SATO, Masayuki , HORIUCHI, Takashi , YAMASHITA, Toru
发明人： NISSAN CHEMICAL INDUSTRIES, LTD.
IPC分类号： C07D498/04
CPC分类号： C07D498/04
摘要： Benzopyran derivatives of formula (I), wherein X and X are absent or represent an oxygen atom; X represents an oxygen atom, a sulfur atom, a nitrogen atom (said nitrogen atom is unsubstituted or substituted by a hydrogen atom or C1-C4 alkyl group), carbonyl or thiocarbonyl; A represents a hydroxyl group or may form a single bond together with B; B represents a hydrogen atom or may form a single bond together with A; Y represents 1-pyrrolyl group, 1-pyrazolyl group, 1-imidazolyl group, 1-(1,2,3-triazolyl) group or 1-(1,2,4-triazolyl) group which is unsubstituted or substituted by R ; R and R independently represent a hydrogen atom, a phenyl group or a C1-C4 alkyl group; R represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group and medicines for treating cardiac insufficiency containing said compound as an active ingredient. The compounds have a strong activity of reinforcing the contraction of cardiac muscles and a strong activity of reducing the heart rate. As the compounds are not toxic, they are useful medicines for treating cardiac insufficiency.
摘要翻译：式（I）的苯并吡喃衍生物，其中X 1和X 2不存在或表示氧原子; X表示氧原子，硫原子，氮原子（所述氮原子未被取代或被氢原子或C1-C4烷基取代），羰基或硫代羰基; A表示羟基或可与B一起形成单键; B代表氢原子或与A形成单键; Y表示未取代或被R 1取代的1-吡咯基，1-吡唑基，1-咪唑基，1-（1,2,3-三唑基）或1-（1,2,4-三唑基） 3>; R 1和R 2独立地表示氢原子，苯基或C 1 -C 4烷基; R 3表示氢原子，卤素原子，C 1 -C 6烷基和用于治疗含有所述化合物作为有效成分的心功能不全的药物。这些化合物具有强化心肌收缩的活性和降低心率的强烈活性。由于化合物没有毒性，它们是治疗心功能不全的有用药物。

10. 发明申请

WO1997044377A1 MELAMINE POLYMETAPHOSPHATE AND PROCESS FOR ITS PRODUCTION 审中-公开
标题翻译：聚甲基丙烯酸甲酯及其生产工艺
公开(公告)号：WO1997044377A1
公开(公告)日：1997-11-27
申请号：PCT/JP1997001712
申请日：1997-05-21
申请人： NISSAN CHEMICAL INDUSTRIES, LTD. , SUZUKI, Keitaro , SHISHIDO, Kouji , SHINDO, Masuo
发明人： NISSAN CHEMICAL INDUSTRIES, LTD.
IPC分类号： C08G79/02
CPC分类号： C08K5/34928 , C08G79/02 , C08K5/529
摘要： A melamine polymetaphosphate having a solubility of from 0.01 to 0.10 g/100 ml in water at 25 DEG C, a pH of from 2.5 to 4.5 in the form of a 10 wt.% aqueous slurry at 25 DEG C and a melamine content of from 1.0 to 1.1 mol per mol of phosphorus atom. A process for producing such a melamine polymetaphosphate, which comprises the following steps (a) and (b): (a) a step of mixing melamine, urea and an aqueous orthophosphoric acid solution containing at least 40 wt.% of orthophosphoric acid, in such a ratio that melamine is from 1.0 to 1.5 mol per mol of orthophosphoric acid and urea is from 0.1 to 1.5 mol per mol of orthophosphoric acid, at a temperature of from 0 to 140 DEG C, to form a reaction mixture, and stirring the reaction mixture at a temperature of from 0 to 140 DEG C, while removing water, to obtain a powdery product of a double salt of orthophosphoric acid with melamine and urea; and (b) a step of calcining the powdery product obtained in step (a) at a temperature of from 240 to 340 DEG C for from 0.1 to 30 hours, while preventing agglomeration, to obtain a melamine polymetaphosphate.
摘要翻译：在25℃下在水中溶解度为0.01至0.10g / 100ml，pH为2.5至4.5，在25℃下为10重量％含水浆料形式的三聚氰胺聚偏磷酸钠，三聚氰胺含量为每摩尔磷原子为1.0-1.1摩尔。一种制备这种三聚氰胺聚偏磷酸盐的方法，其包括以下步骤（a）和（b）：（a）将含有至少40重量％正磷酸的三聚氰胺，尿素和正磷酸水溶液混合在三聚氰胺的摩尔比为每摩尔正磷酸为1.0〜1.5摩尔，尿素为0.1〜1.5摩尔/升正磷酸，温度为0〜140℃，形成反应混合物，搅拌反应混合物在0-140℃的温度下，同时除去水，得到正磷酸的双重盐与三聚氰胺和尿素的粉末状产物; 和（b）在240〜340℃的温度下煅烧步骤（a）中得到的粉末状产物0.1〜30小时，同时防止团聚，得到三聚氰胺聚偏磷酸酯的工序。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式